<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Experimental studies showed that aspirin down-regulates the WNT/CTNNB1 (Î²-catenin) signaling pathway in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether aspirin use was associated with lower incidence and superior survival in nuclear CTNNB1-positive <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: In two large prospective studies (the Nurses' Health Study and the Health Professionals Follow-up Study), we collected the information on aspirin use every 2 years from 1980 through 2008 </plain></SENT>
<SENT sid="3" pm="."><plain>We used Cox proportional hazards regression to compute the multivariate hazard ratio for incidence and mortality according to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> CTNNB1 expression patterns </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: During 28 years and 3,166,091 person-years of follow-up, we documented 931 incident cases of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> with available CTNNB1 expression data </plain></SENT>
<SENT sid="5" pm="."><plain>Regular aspirin use was associated with a significantly lower risk of CTNNB1-positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (multivariate HR = 0.65; 95% CI, 0.53-0.80), but not with the risk of CTNNB1-negative <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (multivariate HR = 0.84; 95% CI, 0.70-1.01) </plain></SENT>
<SENT sid="6" pm="."><plain>A formal test of <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of the association according to CTNNB1 expression status did not reach statistical significance (P = 0.07) </plain></SENT>
<SENT sid="7" pm="."><plain>Regular aspirin use after diagnosis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> was associated with better <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific survival among CTNNB1-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> patients (multivariate HR = 0.53; 95% CI, 0.30-0.95) </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, among CTNNB1-negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> patients, post-diagnosis regular aspirin use was not associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific survival (multivariate HR = 1.06; 95% CI, 0.62-1.83) (P = 0.04 for interaction test between aspirin use and CTNNB1 status) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Regular aspirin use was associated with lower incidence of nuclear CTNNB1-positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, and better survival among patients with nuclear CTNNB1-positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Our molecular pathological epidemiology (MPE) study revealed the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> mechanism of aspirin, which might prevent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence and mortality by inhibiting <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumor initiation</z:e> and/or progression in the WNT/CTNNB1-related <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> pathway </plain></SENT>
</text></document>